Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03399448
Other study ID # UPCC# 25416; IRB #826672
Secondary ID
Status Terminated
Phase Phase 1
First received
Last updated
Start date September 5, 2018
Est. completion date October 9, 2020

Study information

Verified date October 2020
Source University of Pennsylvania
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first-in-human trial proposed to test HLA-A*0201 restricted NY-ESO-1 redirected T cells with edited endogenous T cell receptor and PD-1.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date October 9, 2020
Est. primary completion date February 29, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Subjects with a confirmed diagnosis of relapsed refractory multiple myeloma (MM), melanoma, synovial sarcoma, or myxoid/round cell liposarcoma (MRCL) as follows: a. Multiple Myeloma i. Subjects must have a confirmed prior diagnosis of active MM as defined by the International Myeloma Working Group (IMWG) criteria. ii. Subjects must have relapsed or refractory disease after either one of the following: 1. At least 3 prior regimens, which must have contained an alkylating agent, proteasome inhibitor, and immunomodulatory agent (IMiD) OR 2. At least 2 prior regimens if "double-refractory" to a proteasome inhibitor and IMiD, defined as progression on or within 60 days of treatment with these agents. Note: Induction therapy, stem cell transplant, and maintenance therapy, if given sequentially without intervening progression, should be considered as 1 "regimen". iii. Subjects must be at least 90 days since autologous stem cell transplant, if performed. iv. Toxicities from prior therapies, with the exception of alopecia or peripheral neuropathy attributable to bortezomib, must have recovered to grade = 2 according to the Common Toxicity Criteria (CTCAE) 4.0 criteria or to the subject's prior baseline. v. Subjects must have measurable disease per IMWG criteria on study entry, which must include at least 1 of the following: 1. Serum M-spike = 0.5 g/dL* 2. 24 hour (hr) urine M-spike = 200mg 3. Involved serum free light chain (FLC) = 50 mg/L with abnormal ratio 4. Measurable plasmacytoma on exam or imaging 5. Bone marrow plasma cells = 20% - Note: Patients with IgA myeloma in whom serum protein electrophoresis is deemed unreliable, due to co-migration of normal serum proteins with the paraprotein in the beta region, may be considered eligible as long as total serum IgA level is elevated above normal range. b. Melanoma i. Subjects must have a confirmed prior diagnosis of melanoma. ii. Progressed after at least 2 therapy lines. iii. Subjects with BRAF mutant tumors should have received and progressed through, or are intolerant to, BRAF/MEK inhibitor therapy prior to enrollment iv. Patients must have measurable disease per RECIST 1.1 in order to allow assessment of an anti-tumor response. c. Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (MRCL) i. Subjects must have a confirmed prior diagnosis of synovial sarcoma or MRCL. ii. Patients with proven metastatic disease or surgically inoperable local recurrence that have failed first line treatment. iii. Patients must have measurable disease per RECIST 1.1 in order to allow assessment of an anti-tumor response. 2. Provides written, informed consent. 3. Subjects = 18 years of age. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 5. Documented NY-ESO-1 and/or LAGE-1 expression on tumor tissue. 6. HLA-A*201 positive 7. Subjects of reproductive potential must agree to use acceptable birth control methods. 8. Adequate vital organ function as defined by: 1. Serum creatinine = 2.5 or estimated creatinine clearance =30 ml/min and not dialysis-dependent. 2. Absolute neutrophil count =1000/µl and platelet count =50,000/µl (=30,000/µl if bone marrow plasma cells are =50% of cellularity for MM patients). 3. Serum glutamic oxaloacetic transaminase (SGOT) = 3x the upper limit of normal and total bilirubin = 2.0 mg/dl (except for patients in whom hyperbilirubinemia is attributed to Gilbert's syndrome). 4. Left ventricular ejection fraction (LVEF) = 45%. LVEF assessment must have been performed within 8 weeks of eligibility confirmation by physician-investigator. Exclusion Criteria: - 1. Pregnant or nursing (lactating) women. - 2. Have inadequate venous access for or contraindications to leukapheresis. - 3. Have any active and uncontrolled infection. - 4. Active hepatitis B or hepatitis C - 5. Human immunodeficiency virus (HIV) infection. - 6. Any uncontrolled medical or psychiatric disorder that would preclude participation as outlined. - 7. New York Heart Association (NYHA) Class III or IV heart failure, unstable angina, or a history of recent (within 6 months) myocardial infarction or sustained (>30 seconds) ventricular tachyarrhythmias. - 8. Received prior gene therapy or gene-modified cellular immunotherapy. Subject may have received, however, non-gene-modified autologous T-cells in association with an anti-myeloma vaccine (e.g., hTERT or MAGEA3) or vaccination against infectious agents (e.g., influenza or pneumococcus) as was performed on our previous studies. - 9. Active auto-immune disease, including connective tissue disease, uveitis, sarcoidosis, inflammatory bowel disease, or multiple sclerosis, or have a history of severe (as judged by the principal investigator) autoimmune disease requiring prolonged immunosuppressive therapy. - 10. Prior allogeneic stem cell transplant. - 11. Prior or active central nervous system (CNS) involvement (e.g. leptomeningeal disease, parenchymal masses) with myeloma. Screening for this (e.g. with lumbar puncture) is not required unless suspicious symptoms or radiographic findings are present. Subjects with calvarial disease that extends intracranially and involves the dura will be excluded, even if cerebrospinal fluid (CSF) is negative for myeloma.

Study Design


Intervention

Biological:
NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1
Autologous T cells transduced with a lentiviral vector to express NY-ESO-1 and electroporated with CRISPR guide RNA to disrupt expression of endogenous TCRa, TCRß and PD-1 (NYCE T Cells).
Drug:
Cyclophosphamide
a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Fludarabine
a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Device:
NY-ESO-1 expression testing
Testing to determine if NY-ESO-1 is expressed on tumor tissue.

Locations

Country Name City State
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (3)

Lead Sponsor Collaborator
University of Pennsylvania Parker Institute for Cancer Immunotherapy, Tmunity Therapeutics

Country where clinical trial is conducted

United States, 

References & Publications (1)

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mck — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Determine safety profile of a single infusion of NYCE T cells by monitoring the frequency and severity of adverse events assessed by the National Cancer Institute (NCI) - Common Toxicity Criteria (v4.03) 5 years
Primary Evaluate Manufacturing Feasibility of NYCE T Cells. Evaluate the percentage of manufacturing products that do not meet release criteria for vector transduction efficiency, gene disruption T cell product purity, viability, sterility or due to tumor contamination. 5 years
Secondary Percentage of patients achieving complete response (CR) before or at Month 6 6 months
Secondary Overall survival (OS) 5 years
Secondary Duration of remission (DOR) 5 years
Secondary Progression- free survival (PFS) 5 years
Secondary Cause of death (COD) when appropriate 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1
Recruiting NCT04111809 - Study of 4 Bone Turnover Markers in Patients With Multiple Myeloma Treated With Intravenous Bisphosphonate in Routine Care